Ponesimod is indicated for the treatment of multiple sclerosis. Ponesimod was developed by Actelion Pharmaceuticals Ltd..
The API has now reached off-patent status, after being launched in 2021.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Ponesimod was exported from India in 2023 , with an average price over the period of $9416 /kg.
The key suppliers were Metrochem API, with a focus on markets in Central & South America.

For enquiries regarding more detailed trade data of Ponesimod and many others, contact info@pharmacheminvestor.com